共 130 条
[1]
Hess CN(2017)Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome Am Heart J 187 194-203
[2]
Clare RM(2021)Lp(a) level: when and how to measure it Ann Clin Biochem 58 16-21
[3]
Neely ML(2019)Lipoprotein(a) as an old and new causal risk factor of atherosclerotic cardiovascular disease J Atheroscler Thromb 26 583-591
[4]
Tricoci P(2020)2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk Eur Heart J 41 111-188
[5]
Mahaffey KW(2019)Lipoprotein(a), PCSK9 Inhibition, and cardiovascular risk Circulation 139 1483-1492
[6]
James SK(2021)Residual cardiovascular risk at low LDL: remnants, Lipoprotein(a), and inflammation Clin Chem 67 143-153
[7]
Cegla J(2020)Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial Eur Heart J 41 4245-4255
[8]
France M(1995)Effects of Lowering Elevated LDL Cholesterol on the Cardiovascular Risk of Lipoprotein(A) JAMA 274 1771-1774
[9]
Marcovina SM(2020)Risks of incident cardiovascular disease associated with concomitant elevations in Lipoprotein(a) and low-density lipoprotein cholesterol-the Framingham Heart Study J Am Heart Assoc. 9 e014711-527
[10]
Neely R(2014)Lipoprotein(a) for risk assessment in patients with established coronary artery disease J Am Coll Cardiol 63 520-738